CART19-GOT2

CART19-GOT2 is an experimental CAR-T cell therapy engineered to target CD19-expressing hematologic malignancies while incorporating metabolic modifications to enhance performance in the immunosuppressive and nutrient-depleted tumor microenvironment. The therapy consists of T cells transduced with a chimeric antigen receptor (CAR) specific for CD19 and simultaneously overexpressing the mitochondrial enzyme glutamic-oxaloacetic transaminase 2 (GOT2). GOT2 plays a pivotal role in the malate-aspartate shuttle, converting oxaloacetate to aspartate, thereby maintaining redox balance and energy production. By elevating intracellular aspartate levels, CART19-GOT2 cells exhibit superior mitochondrial fitness, enhanced spare respiratory capacity, and sustained cytolytic activity under hypoxic conditions. Preclinical data demonstrate that these cells can prevent tumor regrowth in leukemia models and suggest potential efficacy in solid tumor immunotherapy where metabolic exhaustion is a significant barrier.

Other names

GOT2-overexpressing CAR-T cellsGOT-2-overexpressing CAR-T cellsGOT 2-overexpressing CAR-T cellsCART19-GOT2 cellsCART-19-GOT2 cellsCART 19-GOT2 cells